International Congress Munich 2014


Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases"

Symposium
Chairs: F. Blasi (Milan, Italy), S. Bonini (London, United Kingdom)
Aims: In this joint ERS/EMA symposium, the audience will:
- Gain a better understanding of the gaps and problems related to rare lung diseases (RLD) endpoints, and their effects on the development and on the regulatory assessment of medicines in this area;
- Increase their knowledge about the state-of-the-art and future clinical development perspectives in the areas of idiopathic pulmonary fibrosis (IPF), critical respiratory conditions and cystic fibrosis (CF); and
- Gain insight into regulatory requirements for development of new medicines in rare diseases.
Development of medicines for rare diseases: where are the problems?
L. Fregonese (London, United Kingdom)
Slide presentation
Slide presentation
Do the current endpoints in IPF clinical trials allow good regulatory decisions to be made?
P. Noble (Durham, United States of America)
WebcastSlide presentationMultimedia files
WebcastSlide presentationMultimedia files
Why are clinical trials in critically-ill respiratory patients relatively uninformative?
P. Pelosi (Genoa, Italy)
WebcastSlide presentationMultimedia files
WebcastSlide presentationMultimedia files
Evaluating disease-modifying treatment in CF: are we ready to take the challenge?
I. Eichler (London, United Kingdom)
WebcastSlide presentationMultimedia files
WebcastSlide presentationMultimedia files